The report is titled as ‘Compounding Chemotherapy Market: Opportunity Analysis and Future Assessment 2020-2028’. An overview of conceptual frameworks, analytical approaches of the compounding chemotherapy market is the main objective of the report, which further consists of the market opportunity and insights of the data involved in the making of the respective market. The compounding chemotherapy market is expected to grow at a significant rate in the near future.
The global compounding chemotherapy market was valued US$ 438.9 Mn at the end of 2020 and expected to reach at a value of US$ 761.0 Mn by 2028 with a significant CAGR of 7.1%.
Compounding can be perceived as the branch of knowledge of amalgamating and making medications and drugs that are specific and unexceptional to the necessities of the patients. These anticancer drugs are developed based on the counsel of the healthcare professional in which the singular elements are combined in conformity with the prescribed dose. The qualified and skilled healthcare workers are allowed to update the prescription for the patient fulfilling their particular needs, including dosage formulations, flavors, deficiency of constituents, and strengths for which the patient is allergic or susceptible.
The rapid enormous evolution in the healthcare industry in the past couple of decades along with various technological advancements is majorly promoting the idea of compounding chemotherapy in the healthcare sector all around the world, which is ultimately expected to offer major breakthroughs to the growth of the global compounding chemotherapy market in the future years.
By the same token, many pioneering and cutting-edge approaches and strategies have authorized pharmacies to retort to the requirements of medics and propel the growth of the global compounding chemotherapy market in the near future.
Furthermore, the growing lack of opium is also estimated to raise demand worldwide for compounding chemotherapy. Such factors are further anticipated to positively fuel the growth of the global compounding chemotherapy market in the years to come. Other than that, hospitals and other health care professionals are further providing consumers all around the world to obtain benefits from compounded medications, which is ultimately projected to accelerate the growth of the global compounding chemotherapy market in the coming years.
The global compounding chemotherapy market is segmented on the basis of Dose, Compounding Type, Delivery Method, Sterility, Technology, Compounder Type, Application, and Region. The dose segment of the compounding chemotherapy market is divided into chemotherapeutic and non-chemotherapeutics. On the basis of compounding type, the market is segmented into pharmaceutical ingredient alteration (PIA), currently unavailable pharmaceutical manufacturing (CUPM), and pharmaceutical dosage alteration (PDA). Then, on the basis of delivery method, the market is bifurcated into a gravimetric automated compounding device (weight-based) and volumetric automated compounding device (volume-based). The global compounding chemotherapy market, by sterility, has been segmented into sterile and non-sterile.
The market for the global compounding chemotherapy market, by technology, is bifurcated into with robotic arms and without robotic arms. By compounder type, the market is bifurcated into Pharmoduct, Equashield Pro, Medimix, Integra, and others. Further, the application segment is divided into breast cancer, blood cancer, prostate cancer, gastrointestinal cancer, respiratory/lung cancer, and others. By Region, market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.
The global compounding chemotherapy market is dominated by Braun Melsungen AG, Pfizer Inc., Baxter, Grifols SA, The Metrix Company, Added Pharma, Equashield, Millers Pharmacy, Comecer S.P.A., Omnicell, Icon group, Dedalus Group, Arxium, Sterline S.R.L., and Loccioni, among others.
The non-identical approach of Meridian Market Consultants stands with conceptual methods backed up with the data analysis. The novel market understanding approach makes up the standard of the assessment results that give a better opportunity for the customers to put their effort.
A research report on the compounding chemotherapy market by Meridian Market Consultants is an in-depth and extensive study of the market based on the necessary data crunching and statistical analysis. It provides a brief view of the dynamics flowing through the market, which includes the factors that support the market and the factors that are acting as impedance for the growth of the market.
Furthermore, the report includes the various trends and opportunities in the respective market in different regions for a better understanding of readers that helps to analyze the potential of the market.
Various factors that are benchmarked while estimating the market growth includes (but not restricted to):
New product designs and launches
Current product compliance
Reimbursement
Concerns for use of compounding chemotherapy
Advantages of compounding chemotherapy
Actions taken by the manufacturer and respective regulatory authorities also impact the market growth of the segment. These factors are understood at regional level and in major countries globally for providing regional insights of the product segment in the report. This helps our clients to make informed decisions.
A mix of top-down and bottom-up approach is followed to arrive and validate our market value estimations. For a product segment like wherein one/two manufacturer(s) dominates the market, it’s products sales, previous growth rates and market expansion plans are considered to generate market share in the global market.
1. Global Compounding Chemotherapy Market Report Overview
1.1. Introduction
1.2. Report Description
1.3. Methodology
2. Global Compounding Chemotherapy Market Overview
2.1. Introduction
2.1.1. Market Definition
2.1.2. Market Taxonomy
2.2. Executive Summary
2.3. Global Compounding Chemotherapy Market Snapshot
2.4. Global Compounding Chemotherapy Market Size And Forecast, 2020–2028
2.4.1. Introduction
2.4.2. Market Value Forecast And Annual Growth Rate (AGR) Comparison (2020–2028)
2.5. Global Compounding Chemotherapy Market Dynamics
2.5.1. Drivers
2.5.2. Restraints
2.5.3. Opportunity
2.5.4. Trends
2.6. Porter’s Five Forces Model
2.7. SWOT Analysis
3. Compounding Chemotherapy Assessment and Analysis
3.1. Compounding Chemotherapy Impact Analysis
3.2. Actions to encourage use of Compounding Chemotherapy
3.3. Compounding Chemotherapy Promotional Strategy Recommendation
3.4. Road Map Analysis
3.5. GAP Analysis
3.6. Potential Analysis
4. Covid-19 Impact on Compounding Chemotherapy Market
4.1. Impact Analysis of Covid-19 on the global Compounding Chemotherapy market
4.2. Effect On Value Chain
4.3. Business Impact W.R.T Revenue
4.4. Volatility In Price
4.5. Effect On The Overall Trade
4.6. Market Impact Analysis In 2020 (Quarter Wise)
5. Global Compounding Chemotherapy Market, By Dose
5.1. Introduction
5.1.1. Annual Growth Rate Comparison, By Dose
5.1.2. BPS Analysis, By Dose
5.2. Market Revenue (US$Mn) and Forecast, By Dose
5.2.1. Chemotherapeutic
5.2.2. Non-chemotherapeutics
5.3. Global Compounding Chemotherapy Market Attractiveness Index, By Dose
6. Global Compounding Chemotherapy Market, By Compounding Type
6.1. Introduction
6.1.1. Annual Growth Rate Comparison, By Compounding Type
6.1.2. BPS Analysis, By Compounding Type
6.2. Market Revenue (US$Mn) and Forecast, By Compounding Type
6.2.1. Pharmaceutical Ingredient Alteration (PIA)
6.2.2. Currently Unavailable Pharmaceutical Manufacturing (CUPM)
6.2.3. Pharmaceutical Dosage Alteration
6.3. Global Compounding Chemotherapy Market Attractiveness Index, By Compounding Type
7. Global Compounding Chemotherapy Market, By Delivery Method
7.1. Introduction
7.1.1. Annual Growth Rate Comparison, By Delivery Method
7.1.2. BPS Analysis, By Delivery Method
7.2. Market Revenue (US$Mn) and Forecast, By Delivery Method
7.2.1. Gravimetric Automated Compounding Device (Weight-based)
7.2.2. Volumetric Automated Compounding Device (Volume-based)
7.3. Global Compounding Chemotherapy Market Attractiveness Index, By Delivery Method
8. Global Compounding Chemotherapy Market, By Sterility
8.1. Introduction
8.1.1. Annual Growth Rate Comparison, By Sterility
8.1.2. BPS Analysis, By Sterility
8.2. Market Revenue (US$Mn) and Forecast, By Sterility
8.2.1. Sterile
8.2.2. Non-sterile
8.3. Global Compounding Chemotherapy Market Attractiveness Index, By Sterility
9. Global Compounding Chemotherapy Market, By Technology
9.1. Introduction
9.1.1. Annual Growth Rate Comparison, By Technology
9.1.2. BPS Analysis, By Technology
9.2. Market Revenue (US$Mn) and Forecast, By Technology
9.2.1. With Robotic Arms
9.2.2. Without Robotic Arms
9.3. Global Compounding Chemotherapy Market Attractiveness Index, By Technology
10. Global Compounding Chemotherapy Market, By Compounder Type
10.1. Introduction
10.1.1. Annual Growth Rate Comparison, By Compounder Type
10.1.2. BPS Analysis, By Compounder Type
10.2. Market Revenue (US$Mn) and Forecast, By Compounder Type
10.2.1. Pharmoduct
10.2.2. Equashield Pro
10.2.3. Medimix
10.2.4. Integra
10.2.5. Others
10.3. Global Compounding Chemotherapy Market Attractiveness Index, By Compounder Type
11. Global Compounding Chemotherapy Market, By Application
11.1. Introduction
11.1.1. Annual Growth Rate Comparison, By Application
11.1.2. BPS Analysis, By Application
11.2. Market Revenue (US$Mn) and Forecast, By Application
11.2.1. Breast Cancer
11.2.2. Blood Cancer
11.2.3. Prostate Cancer
11.2.4. Gastrointestinal Cancer
11.2.5. Respiratory/Lunch Cancer
11.2.6. Others
11.3. Global Compounding Chemotherapy Market Attractiveness Index, By Application
12. Global Compounding Chemotherapy Market, By Region
12.1. Introduction
12.1.1. Annual Growth Rate Comparison, By Region
12.1.2. BPS Analysis, By Region
12.2. Market Revenue (US$Mn) and Forecast, By Region
12.2.1. North America
12.2.2. Latin America
12.2.3. Europe
12.2.4. Asia Pacific
12.2.5. Middle East
12.2.6. Africa
12.3. Global Compounding Chemotherapy Market Attractiveness Index, By Region
13. North America Compounding Chemotherapy Market Analysis and Forecast, 2020–2028
13.1. Introduction
13.1.1. Annual Growth Rate Comparison, By Country
13.1.2. BPS Analysis, By Country
13.2. Market Revenue (US$Mn) and Forecast, By Country
13.2.1. U.S. Compounding Chemotherapy Market
13.2.2. Canada Compounding Chemotherapy Market
13.3. North America Compounding Chemotherapy Market, By Dose
13.3.1. Chemotherapeutic
13.3.2. Non-chemotherapeutics
13.4. North America Compounding Chemotherapy Market Revenue (US$Mn) and Forecast, By Compounding Type
13.4.1. Pharmaceutical Ingredient Alteration (PIA)
13.4.2. Currently Unavailable Pharmaceutical Manufacturing (CUPM)
13.4.3. Pharmaceutical Dosage Alteration
13.5. North America Compounding Chemotherapy Market Revenue (US$Mn) and Forecast, By Delivery Method
13.5.1. Gravimetric Automated Compounding Device (Weight-based)
13.5.2. Volumetric Automated Compounding Device (Volume-based)
13.6. North America Compounding Chemotherapy Market Revenue (US$Mn) and Forecast, By Sterility
13.6.1. Sterile
13.6.2. Non-sterile
13.7. North America Compounding Chemotherapy Market Revenue (US$Mn) and Forecast, By Technology
13.7.1. With Robotic Arms
13.7.2. Without Robotic Arms
13.8. North America Compounding Chemotherapy Market Revenue (US$Mn) and Forecast, By Compounder Type
13.8.1. Pharmoduct
13.8.2. Equashield Pro
13.8.3. Medimix
13.8.4. Integra
13.8.5. Others
13.9. North America Compounding Chemotherapy Market Revenue (US$Mn) and Forecast, By Application
13.9.1. Breast Cancer
13.9.2. Blood Cancer
13.9.3. Prostate Cancer
13.9.4. Gastrointestinal Cancer
13.9.5. Respiratory/Lunch Cancer
13.9.6. Others
13.10. North America Compounding Chemotherapy Market Attractiveness Index
13.10.1. By Country
13.10.2. By Dose
13.10.3. By Compounding Type
13.10.4. By Delivery Method
13.10.5. By Sterility
13.10.6. By Technology
13.10.7. By Compounder Type
13.10.8. By Application
14. Latin America Compounding Chemotherapy Market Analysis and Forecast, 2020–2028
14.1. Introduction
14.1.1. Annual Growth Rate Comparison, By Country
14.1.2. BPS Analysis, By Country
14.2. Market (US$Mn) Forecast, By Country
14.2.1. Brazil Compounding Chemotherapy Market
14.2.2. Mexico Compounding Chemotherapy Market
14.2.3. Rest Of Latin America Compounding Chemotherapy Market
14.3. Latin America Compounding Chemotherapy Market, By Dose
14.3.1. Chemotherapeutic
14.3.2. Non-chemotherapeutics
14.4. Latin America Compounding Chemotherapy Market Revenue (US$Mn) and Forecast, By Compounding Type
14.4.1. Pharmaceutical Ingredient Alteration (PIA)
14.4.2. Currently Unavailable Pharmaceutical Manufacturing (CUPM)
14.4.3. Pharmaceutical Dosage Alteration
14.5. Latin America Compounding Chemotherapy Market Revenue (US$Mn) and Forecast, By Delivery Method
14.5.1. Gravimetric Automated Compounding Device (Weight-based)
14.5.2. Volumetric Automated Compounding Device (Volume-based)
14.6. Latin America Compounding Chemotherapy Market Revenue (US$Mn) and Forecast, By Sterility
14.6.1. Sterile
14.6.2. Non-sterile
14.7. Latin America Compounding Chemotherapy Market Revenue (US$Mn) and Forecast, By Technology
14.7.1. With Robotic Arms
14.7.2. Without Robotic Arms
14.8. Latin America Compounding Chemotherapy Market Revenue (US$Mn) and Forecast, By Compounder Type
14.8.1. Pharmoduct
14.8.2. Equashield Pro
14.8.3. Medimix
14.8.4. Integra
14.8.5. Others
14.9. Latin America Compounding Chemotherapy Market Revenue (US$Mn) and Forecast, By Application
14.9.1. Breast Cancer
14.9.2. Blood Cancer
14.9.3. Prostate Cancer
14.9.4. Gastrointestinal Cancer
14.9.5. Respiratory/Lunch Cancer
14.9.6. Others
14.10. Latin America Compounding Chemotherapy Market Attractiveness Index
14.10.1. By Country
14.10.2. By Dose
14.10.3. By Compounding Type
14.10.4. By Delivery Method
14.10.5. By Sterility
14.10.6. By Technology
14.10.7. By Compounder Type
14.10.8. By Application
15. Europe Compounding Chemotherapy Market Analysis and Forecast, 2020–2028
15.1. Introduction
15.1.1. Annual Growth Rate Comparison, By Country
15.1.2. BPS Analysis, By Country
15.2. Market (US$Mn) Forecast, By Country
15.2.1. U.K. Compounding Chemotherapy Market
15.2.2. Germany Compounding Chemotherapy Market
15.2.3. Italy Compounding Chemotherapy Market
15.2.4. France Compounding Chemotherapy Market
15.2.5. Spain Compounding Chemotherapy Market
15.2.6. Russia Compounding Chemotherapy Market
15.2.7. Rest Of Europe Compounding Chemotherapy Market
15.3. Europe Compounding Chemotherapy Market, By Dose
15.3.1. Chemotherapeutic
15.3.2. Non-chemotherapeutics
15.4. Europe Compounding Chemotherapy Market Revenue (US$Mn) and Forecast, By Compounding Type
15.4.1. Pharmaceutical Ingredient Alteration (PIA)
15.4.2. Currently Unavailable Pharmaceutical Manufacturing (CUPM)
15.4.3. Pharmaceutical Dosage Alteration
15.5. Europe Compounding Chemotherapy Market Revenue (US$Mn) and Forecast, By Delivery Method
15.5.1. Gravimetric Automated Compounding Device (Weight-based)
15.5.2. Volumetric Automated Compounding Device (Volume-based)
15.6. Europe Compounding Chemotherapy Market Revenue (US$Mn) and Forecast, By Sterility
15.6.1. Sterile
15.6.2. Non-sterile
15.7. Europe Compounding Chemotherapy Market Revenue (US$Mn) and Forecast, By Technology
15.7.1. With Robotic Arms
15.7.2. Without Robotic Arms
15.8. Europe Compounding Chemotherapy Market Revenue (US$Mn) and Forecast, By Compounder Type
15.8.1. Pharmoduct
15.8.2. Equashield Pro
15.8.3. Medimix
15.8.4. Integra
15.8.5. Others
15.9. Europe Compounding Chemotherapy Market Revenue (US$Mn) and Forecast, By Application
15.9.1. Breast Cancer
15.9.2. Blood Cancer
15.9.3. Prostate Cancer
15.9.4. Gastrointestinal Cancer
15.9.5. Respiratory/Lunch Cancer
15.9.6. Others
15.10. Europe Compounding Chemotherapy Market Attractiveness Index
15.10.1. By Country
15.10.2. By Dose
15.10.3. By Compounding Type
15.10.4. By Delivery Method
15.10.5. By Sterility
15.10.6. By Technology
15.10.7. By Compounder Type
15.10.8. By Application
16. Asia Pacific Compounding Chemotherapy Market Analysis and Forecast, 2020–2028
16.1. Introduction
16.1.1. Annual Growth Rate Comparison, By Country
16.1.2. BPS Analysis, By Country
16.2. Market (US$Mn) Forecast, By Country
16.2.1. China Compounding Chemotherapy Market
16.2.2. India Compounding Chemotherapy Market
16.2.3. Japan Compounding Chemotherapy Market
16.2.4. Australia and New Zealand Compounding Chemotherapy Market
16.2.5. South Korea Compounding Chemotherapy Market
16.2.6. Rest of Asia Pacific Compounding Chemotherapy Market
16.3. Asia Pacific Compounding Chemotherapy Market, By Dose
16.3.1. Chemotherapeutic
16.3.2. Non-chemotherapeutics
16.4. Asia Pacific Compounding Chemotherapy Market Revenue (US$Mn) and Forecast, By Compounding Type
16.4.1. Pharmaceutical Ingredient Alteration (PIA)
16.4.2. Currently Unavailable Pharmaceutical Manufacturing (CUPM)
16.4.3. Pharmaceutical Dosage Alteration
16.5. Asia Pacific Compounding Chemotherapy Market Revenue (US$Mn) and Forecast, By Delivery Method
16.5.1. Gravimetric Automated Compounding Device (Weight-based)
16.5.2. Volumetric Automated Compounding Device (Volume-based)
16.6. Asia Pacific Compounding Chemotherapy Market Revenue (US$Mn) and Forecast, By Sterility
16.6.1. Sterile
16.6.2. Non-sterile
16.7. Asia Pacific Compounding Chemotherapy Market Revenue (US$Mn) and Forecast, By Technology
16.7.1. With Robotic Arms
16.7.2. Without Robotic Arms
16.8. Asia Pacific Compounding Chemotherapy Market Revenue (US$Mn) and Forecast, By Compounder Type
16.8.1. Pharmoduct
16.8.2. Equashield Pro
16.8.3. Medimix
16.8.4. Integra
16.8.5. Others
16.9. Asia Pacific Compounding Chemotherapy Market Revenue (US$Mn) and Forecast, By Application
16.9.1. Breast Cancer
16.9.2. Blood Cancer
16.9.3. Prostate Cancer
16.9.4. Gastrointestinal Cancer
16.9.5. Respiratory/Lunch Cancer
16.9.6. Others
16.10. Asia Pacific Compounding Chemotherapy Market Attractiveness Index
16.10.1. By Country
16.10.2. By Dose
16.10.3. By Compounding Type
16.10.4. By Delivery Method
16.10.5. By Sterility
16.10.6. By Technology
16.10.7. By Compounder Type
16.10.8. By Application
17. Middle East Compounding Chemotherapy Market Analysis and Forecast, 2020–2028
17.1. Introduction
17.1.1. Annual Growth Rate Comparison, By Country
17.1.2. BPS Analysis, By Country
17.2. Market (US$Mn) Forecast, By Country
17.2.1. GCC Countries Compounding Chemotherapy Market
17.2.2. Israel Compounding Chemotherapy Market
17.2.3. Rest Of Middle East Compounding Chemotherapy Market
17.3. Middle East Compounding Chemotherapy Market, By Dose
17.3.1. Chemotherapeutic
17.3.2. Non-chemotherapeutics
17.4. Middle East Compounding Chemotherapy Market Revenue (US$Mn) and Forecast, By Compounding Type
17.4.1. Pharmaceutical Ingredient Alteration (PIA)
17.4.2. Currently Unavailable Pharmaceutical Manufacturing (CUPM)
17.4.3. Pharmaceutical Dosage Alteration
17.5. Middle East Compounding Chemotherapy Market Revenue (US$Mn) and Forecast, By Delivery Method
17.5.1. Gravimetric Automated Compounding Device (Weight-based)
17.5.2. Volumetric Automated Compounding Device (Volume-based)
17.6. Middle East Compounding Chemotherapy Market Revenue (US$Mn) and Forecast, By Sterility
17.6.1. Sterile
17.6.2. Non-sterile
17.7. Middle East Compounding Chemotherapy Market Revenue (US$Mn) and Forecast, By Technology
17.7.1. With Robotic Arms
17.7.2. Without Robotic Arms
17.8. Middle East Compounding Chemotherapy Market Revenue (US$Mn) and Forecast, By Compounder Type
17.8.1. Pharmoduct
17.8.2. Equashield Pro
17.8.3. Medimix
17.8.4. Integra
17.8.5. Others
17.9. Middle East Compounding Chemotherapy Market Revenue (US$Mn) and Forecast, By Application
17.9.1. Breast Cancer
17.9.2. Blood Cancer
17.9.3. Prostate Cancer
17.9.4. Gastrointestinal Cancer
17.9.5. Respiratory/Lunch Cancer
17.9.6. Others
17.10. Middle East Compounding Chemotherapy Market Attractiveness Index
17.10.1. By Country
17.10.2. By Dose
17.10.3. By Compounding Type
17.10.4. By Delivery Method
17.10.5. By Sterility
17.10.6. By Technology
17.10.7. By Compounder Type
17.10.8. By Application
18. Africa Compounding Chemotherapy Market Analysis and Forecast, 2020–2028
18.1. Introduction
18.1.1. Annual Growth Rate Comparison, By Country
18.1.2. BPS Analysis, By Country
18.2. Market (US$Mn) Forecast, By Country
18.2.1. South Africa Countries Compounding Chemotherapy Market
18.2.2. Egypt Compounding Chemotherapy Market
18.2.3. North Africa Compounding Chemotherapy Market
18.2.4. Rest of Africa Compounding Chemotherapy Market
18.3. Africa Compounding Chemotherapy Market, By Dose
18.3.1. Chemotherapeutic
18.3.2. Non-chemotherapeutics
18.4. Africa Compounding Chemotherapy Market Revenue (US$Mn) and Forecast, By Compounding Type
18.4.1. Pharmaceutical Ingredient Alteration (PIA)
18.4.2. Currently Unavailable Pharmaceutical Manufacturing (CUPM)
18.4.3. Pharmaceutical Dosage Alteration
18.5. Africa Compounding Chemotherapy Market Revenue (US$Mn) and Forecast, By Delivery Method
18.5.1. Gravimetric Automated Compounding Device (Weight-based)
18.5.2. Volumetric Automated Compounding Device (Volume-based)
18.6. Africa Compounding Chemotherapy Market Revenue (US$Mn) and Forecast, By Sterility
18.6.1. Sterile
18.6.2. Non-sterile
18.7. Africa Compounding Chemotherapy Market Revenue (US$Mn) and Forecast, By Technology
18.7.1. With Robotic Arms
18.7.2. Without Robotic Arms
18.8. Africa Compounding Chemotherapy Market Revenue (US$Mn) and Forecast, By Compounder Type
18.8.1. Pharmoduct
18.8.2. Equashield Pro
18.8.3. Medimix
18.8.4. Integra
18.8.5. Others
18.9. Africa Compounding Chemotherapy Market Revenue (US$Mn) and Forecast, By Application
18.9.1. Breast Cancer
18.9.2. Blood Cancer
18.9.3. Prostate Cancer
18.9.4. Gastrointestinal Cancer
18.9.5. Respiratory/Lunch Cancer
18.9.6. Others
18.10. Africa Compounding Chemotherapy Market Attractiveness Index
18.10.1. By Country
18.10.2. By Dose
18.10.3. By Compounding Type
18.10.4. By Delivery Method
18.10.5. By Sterility
18.10.6. By Technology
18.10.7. By Compounder Type
18.10.8. By Application
19. Competitive Landscape
19.1. Company Profiles
19.1.1. Braun Melsungen AG
19.1.1.1. Company Overview
19.1.1.2. Financial Overview
19.1.1.3. Key Developments
19.1.1.4. Strategies
19.1.1.5. Product Analysis
19.1.2. Pfizer Inc.
19.1.3. Baxter, Grifols SA
19.1.4. The Metrix Company
19.1.5. Added Pharma
19.1.6. Equashield
19.1.7. Millers Pharmacy
19.1.8. Comecer S.P.A.
19.1.9. Omnicell
19.1.10. Icon group
19.1.11. Dedalus Group
19.1.12. Arxium
19.1.13. Sterline S.R.L.
19.1.14. Loccioni
20. Acronyms